Newly-released Virtual Clinical Trials industry analysis report by Transparency Market Research shows that global sales of Virtual Clinical Trials in 2021 was held at US$ 7.6 Bn. With 7.4% projected growth during 2022 – 2032, the market is expected to reach a valuation of US$ 16.4 Bn. Interventional Design is expected to be the highest revenue generating type, accounting for an absolute dollar opportunity of nearly US$ 8.3 Bn during 2022 – 2032.
|
Attribute |
Details |
|
|
Global Virtual Clinical Trials Market (2022) |
US$ 8 Bn |
|
|
Global Virtual Clinical Trials Market (2032) |
US$ 16.4 Bn |
|
|
Global Virtual Clinical Trials Market CAGR (2022 – 2032) |
7.4% |
|
|
North America Virtual Clinical Trials Market (2022) |
US$ 3.4 Bn |
|
|
U.S. Virtual Clinical Trials Market (2022) |
US$ 3 Bn |
|
|
Key Companies Profiled |
|
As per the Virtual Clinical Trials industry research by Transparency Market Research - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the Virtual Clinical Trials industry increased at around 5.8% CAGR, wherein, countries such as the U.S., UK, China, South Korea and Japan held significant share in the global market. Owing to this, Virtual Clinical Trials Market is projected to grow at a CAGR of 7.4% over the coming 10 years.
According to a study published in April 2020, around 30% of the evaluated clinical trial sites are predicted to have a substantial impact on enrolling patients for new trial investigations as well as keeping patients engaged in studies on track. Furthermore, patients are less likely to continue participating in research, according to 81% of European clinical trial study sites and 56% of US sites. Furthermore, roughly 30 pharmaceutical or biotech startups had reported trial disruption as a result of the crisis as of March 30. Virtual trials, also called as decentralised trials, were critical in the COVID-19 crisis and are expected to become the norm in how trials as well as real-world studies will be done in the future.
A virtual method allows people to participate in the trial from the comfort of their own homes, ensuring that research can proceed even when site visits are not possible, and thus represents a novel approach to collecting safety and efficacy data from clinical study participants. Participants have the option and peace of mind of not being exposed to excessive risk owing to virtual visits and remote monitoring of in-person site visits.
Sponsors can include a larger population in virtual studies, which improves recruiting efforts, engagement, and retention. It also allows for continuous real-time collection of data via digital health technologies. Virtual connectivity, monitoring, and management can eventually reduce the effort, time commitment, and burden on participants, CRCs, and investigators.
Due to rising demand for Virtual Clinical Trials in developing nations, particularly India and China, the market in Asia Pacific is predicted to grow at the fastest rate throughout the forecast period.
The market in the region is expected to grow throughout the forecast period as advanced healthcare infrastructure continues to be modernized.
The market for virtual clinical trials in Asia Pacific is expected to grow at the fastest CAGR of 6.8% during the forecast period, owing to the increasing availability of a large patient pool allowing for easy recruitment of candidates, as well as increased penetration of digital technologies in the region.
In 2021, the United States dominated the virtual clinical trials industry, accounting for over 35% of revenue. The country is likely to maintain its dominance over the predicted period. This is attributable to increased research and development in the region, as well as greater adoption of new technology in clinical research and government assistance. In addition, industry actors are utilizing digital technology to satisfy their customers' needs. For example, Parexel conducted more than 100 decentralized experiments, including hybrid and virtual techniques. Patients can participate in the research at one of Covance's nearly 1,900 LabCorp Patient Service Centers across the United States.
Virtual clinical trials market in the U.K. was valued at US$ 290.6 Mn in 2021. By 2032, the market in the country is projected to reach a valuation of US$ 520.8 Mn, at a CAGR of 5.2% during 2022-2032, registering an absolute dollar opportunity of US$ 211.1 Mn during this period.
Virtual clinical trials market in Japan is valued at US$ 383 Mn in 2021. The market with an absolute dollar opportunity of US$ 630 Mn is expected to reach a valuation of US$ 1 Bn by 2032. During 2022 – 2032, the market in Japan is expected to witness 10.5% CAGR.
Virtual clinical trials market in South Korea is expected to reach a valuation of US$ 326 Mn by 2032. The market in the country is expected to witness an absolute dollar opportunity of US$ 154 Mn, growing at 6.6% CAGR during 2022 – 2032.
The oncology category dominated the market for Virtual/Decentralized Clinical Trials in 2021, accounting for 25.2% of the total revenue. The category is also estimated to contribute to the largest share of the market throughout the forecast period. This is attributable to a rise in the number of cancer cases worldwide as well as the number of oncology clinical studies. Cancer patients were most vulnerable during COVID-19. To keep a person safe and studies moving forward, oncology clinical trial investigators and sponsors have quickly integrated virtual and remote trials.
Furthermore, cancer researchers face significant challenges in patient recruitment. As of June 2019, roughly 14,000 oncology trials were trying to hire, with a participation rate of 3% to 8% of potential candidates, with a much lower participation rate in minority and geriatric populations. Low enrolment rates jeopardize the success of specific clinical studies; they may stymie treatment advancements and the corresponding benefits to outcomes. As a result, the low rate of recruitment and the need for a diverse population for oncology clinical studies are expected to drive the adoption of virtual clinical trials.
In 2021, the interventional design segment accounted for 46.7% of revenue in the Virtual/Decentralized Clinical Trials (DCTs) market. The rapid expansion in the number of tests being undertaken to produce innovative drugs for various ailments, as well as the digitization of laboratories, are driving this industry. Since the traditional method of clinical trials poses a high risk of infection in people, the coronavirus outbreak has boosted the demand for testing and trials of novel vaccines to tackle the issue all over the world. As a result, there is a growing demand for interventional study designs.
Virtual trials are better suitable for chronic diseases and observational studies that require less intervention, such as cardiovascular disease, immunology, gastrointestinal, dermatological, respiratory disease, and endocrinology. The business that pioneered this concept employed its own mobile telemedicine-based platform, "NORA," to perform a Phase 2b "siteless" clinical trial with 372 patients across ten states. The expanded access sector is predicted to grow at the fastest rate during the projection period. Since the continual appearance of new COVID-19 variations is expected to generate demand for extended access to new medications in the short term, expanded access is a viable pathway that is appropriate when the patient's potential benefit outweighs the potential dangers.
The key players in the virtual clinical trials market include ICON, plc; Parexel International Corporation; IQVIA; Covance; PRA Health Sciences; LEO Innovation Lab; Medidata; Oracle; CRF Health; Clinical Ink; and Medable, Inc.
Some of the recent developments of key Virtual Clinical Trials providers are as follows:
Similarly, recent developments related to companies offering Virtual Clinical Trials have been tracked by the team at Transparency Market Research, which are available in the full report.
By Study Design
By Indication
By Region
The global Virtual Clinical Trials market is worth more than US$ 7.6 Bn at present.
The value of Virtual Clinical Trials are projected to increase at a CAGR of around 7.4% during 2022 – 2032.
The value of Virtual Clinical Trials increased at a CAGR of around 5.8% during 2017 – 2021.
The decentralized trials, played an important role in the COVID-19 crisis and are set to be the norm in the way trials and real-world studies are conducted.
Top five players in the Virtual Clinical Trials market include ICON, plc; Parexel International Corporation; IQVIA; Covance; PRA Health Sciences; LEO Innovation Lab; Medidata; Oracle; CRF Health; Clinical Ink; and Medable, Inc.
Top 5 countries driving demand for Virtual Clinical Trials are U.S., U.K., China, Japan, and South Korea.
North America accounted for over 40% of global Virtual Clinical Trials demand in 2021.
The European market for Virtual Clinical Trials is projected to expand at a CAGR of around 5% during 2022 – 2032.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Supply Chain Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
4. Global Virtual Clinical Trials Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Study Design
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Study Design, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Study Design, 2022-2032
5.3.1. Interventional
5.3.2. Observational
5.3.3. Expanded Access
5.4. Y-o-Y Growth Trend Analysis By Study Design, 2017-2021
5.5. Absolute $ Opportunity Analysis By Study Design, 2022-2032
6. Global Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032
6.3.1. Oncology
6.3.2. Cardiovascular
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
7. Global Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Study Design
8.2.3. By Indication
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Study Design
8.3.3. By Indication
8.4. Key Takeaways
9. Latin America Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Rest of Latin America
9.2.2. By Study Design
9.2.3. By Indication
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Study Design
9.3.3. By Indication
9.4. Key Takeaways
10. Europe Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. U.K.
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By Study Design
10.2.3. By Indication
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Study Design
10.3.3. By Indication
10.4. Key Takeaways
11. East Asia Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Study Design
11.2.3. By Indication
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Study Design
11.3.3. By Indication
11.4. Key Takeaways
12. South Asia Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By Study Design
12.2.3. By Indication
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Study Design
12.3.3. By Indication
12.4. Key Takeaways
13. Oceania Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Study Design
13.2.3. By Indication
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Study Design
13.3.3. By Indication
13.4. Key Takeaways
14. MEA Virtual Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC
14.2.1.2. Rest of MEA
14.2.2. By Study Design
14.2.3. By Indication
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Study Design
14.3.3. By Indication
14.4. Key Takeaways
15. Key Countries Virtual Clinical Trials Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Study Design
15.1.2.2. By Indication
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Study Design
15.2.2.2. By Indication
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Study Design
15.3.2.2. By Indication
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Study Design
15.4.2.2. By Indication
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Study Design
15.5.2.2. By Indication
15.6. Germany
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Study Design
15.6.2.2. By Indication
15.7. Italy
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Study Design
15.7.2.2. By Indication
15.8. France
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Study Design
15.8.2.2. By Indication
15.9. U.K.
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Study Design
15.9.2.2. By Indication
15.10. Spain
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Study Design
15.10.2.2. By Indication
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Study Design
15.11.2.2. By Indication
15.12. BENELUX
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Study Design
15.12.2.2. By Indication
15.13. China
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Study Design
15.13.2.2. By Indication
15.14. Japan
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Study Design
15.14.2.2. By Indication
15.15. South Korea
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Study Design
15.15.2.2. By Indication
15.16. India
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Study Design
15.16.2.2. By Indication
15.17. Thailand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Study Design
15.17.2.2. By Indication
15.18. Malaysia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Study Design
15.18.2.2. By Indication
15.19. Indonesia
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Study Design
15.19.2.2. By Indication
15.20. Australia
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Study Design
15.20.2.2. By Indication
15.21. New Zealand
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2021
15.21.2.1. By Study Design
15.21.2.2. By Indication
15.22. GCC Countries
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2021
15.22.2.1. By Study Design
15.22.2.2. By Indication
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Study Design
16.3.3. By Indication
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. ICON, plc
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Parexel International Corporation
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. IQVIA
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Covance
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. PRA Health Sciences
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. LEO Innovation Lab
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Medidata
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Oracle
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. CRF Health
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Clinical Ink
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Medable, Inc.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
List of Tables
Table 1: Global Virtual Clinical Trials Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 3: Global Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 4: North America Virtual Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 5: North America Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 6: North America Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 7: Latin America Virtual Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: Latin America Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 9: Latin America Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 10: Europe Virtual Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 11: Europe Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 12: Europe Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 13: East Asia Virtual Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: East Asia Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 15: East Asia Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 16: South Asia Virtual Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 17: South Asia Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 18: South Asia Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 19: Oceania Virtual Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 20: Oceania Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 21: Oceania Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 22: MEA Virtual Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 23: MEA Virtual Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 24: MEA Virtual Clinical Trials Market Value (US$ Mn) Forecast by Indication, 2017-2032
List of Figure
Figure 1: Global Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 2: Global Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 3: Global Virtual Clinical Trials Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Virtual Clinical Trials Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 5: Global Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 6: Global Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 7: Global Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 8: Global Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 9: Global Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 10: Global Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 11: Global Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 12: Global Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 13: Global Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 14: Global Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 15: Global Virtual Clinical Trials Market Attractiveness by Region, 2022-2032
Figure 16: North America Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 17: North America Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 18: North America Virtual Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Virtual Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 20: North America Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 23: North America Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 24: North America Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 25: North America Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 26: North America Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 27: North America Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 28: North America Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 29: North America Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 30: North America Virtual Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 32: Latin America Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 33: Latin America Virtual Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Virtual Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 35: Latin America Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 38: Latin America Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 39: Latin America Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 40: Latin America Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 41: Latin America Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 42: Latin America Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 43: Latin America Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 44: Latin America Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 45: Latin America Virtual Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 46: Europe Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 47: Europe Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 48: Europe Virtual Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Virtual Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 50: Europe Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 53: Europe Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 54: Europe Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 55: Europe Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 56: Europe Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 57: Europe Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 58: Europe Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 59: Europe Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 60: Europe Virtual Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 61: East Asia Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 62: East Asia Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 63: East Asia Virtual Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 64: East Asia Virtual Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 65: East Asia Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: East Asia Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: East Asia Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 68: East Asia Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 69: East Asia Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 70: East Asia Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 71: East Asia Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 72: East Asia Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 73: East Asia Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 74: East Asia Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 75: East Asia Virtual Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 76: South Asia Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 77: South Asia Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 78: South Asia Virtual Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 79: South Asia Virtual Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 80: South Asia Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: South Asia Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: South Asia Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 83: South Asia Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 84: South Asia Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 85: South Asia Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 86: South Asia Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 87: South Asia Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 88: South Asia Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 89: South Asia Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 90: South Asia Virtual Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 91: Oceania Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 92: Oceania Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 93: Oceania Virtual Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 94: Oceania Virtual Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 95: Oceania Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 96: Oceania Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 97: Oceania Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 98: Oceania Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 99: Oceania Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 100: Oceania Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 101: Oceania Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 102: Oceania Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 103: Oceania Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 104: Oceania Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 105: Oceania Virtual Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 106: MEA Virtual Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 107: MEA Virtual Clinical Trials Market Value (US$ Mn) by Indication, 2022-2032
Figure 108: MEA Virtual Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 109: MEA Virtual Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 110: MEA Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 111: MEA Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 112: MEA Virtual Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 113: MEA Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 114: MEA Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 115: MEA Virtual Clinical Trials Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 116: MEA Virtual Clinical Trials Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 117: MEA Virtual Clinical Trials Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 118: MEA Virtual Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 119: MEA Virtual Clinical Trials Market Attractiveness by Indication, 2022-2032
Figure 120: MEA Virtual Clinical Trials Market Attractiveness by Country, 2022-2032
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Virtual Clinical Trials Market
*86 figures and 60 tables includes